Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,800 total articles
Innovex (INVX) is executing a distribution-led strategy that is lifting margins, cash flow and customer stickiness. With a $2.1B market cap, low leverage and $124m in free cash flow, the stock looks primed for a mid-term re-rating. This trade idea lays out an entry, stop and target with clear catalysts and risks.
Nvidia remains the dominant playbook for AI compute. This trade idea lays out a long entry at $700.00 with a $950.00 target and a $560.00 stop, arguing that secular AI and data-center secular demand justify keeping exposure while recognizing elevated valuation and execution risks.
VitalHub looks like a structurally better business than two years ago: recurring SaaS mix is higher, client retention has stabilized, and management is focused on margins. The stock, however, still trades at a deeply discounted multiple versus reasonable software comps. This trade targets that re-rating with a clear entry, stop and two-stage target…
NXGCF is an OTC microcap mining name showing improving technicals, rising short interest and heavy short-volume days. That mix creates an asymmetric trade: upside if momentum and any positive corporate/catalyst news triggers short covering, but downside if liquidity dries up or dilution appears. Enter at $1.06 with a stop at $0.85 and a mid-term ta…
Boeing's strategic move into Archer's orbit materially reduces execution risk and creates a clear path to commercialization for Archer's Midnight eVTOL. At a $4.43B market cap and $5.29 cash per share, Archer is still priced like a shot-in-the-dark. The Boeing deal compresses key risks and leaves a tradable setup: enter near $5.75, target $9.50 on …
Revolution Medicines (RVMD) just received FDA approval for RASONQUE (daraxonrasib) in metastatic pancreatic cancer and has secured a national specialty pharmacy partner for launch. The binary clinical risk has resolved and analysts model up to $11.5 billion in peak sales; the market cap of $44.6 billion already prices a lot of that optionality but …
BE Semiconductor (BESIY) builds the assembly equipment used for advanced packaging. As AI compute density drives adoption of hybrid bonding at scale, equipment demand and order cadence should accelerate. The stock is trading off recent highs near $374 and looks to be pricing a reset; this trade targets re-rating as hybrid bonding shortages become v…
Dick's Sporting Goods plunged after Q2 and weak Foot Locker metrics, but the selloff has pushed valuation to attractive levels: market cap ~$12.1B, P/E ~13.4, EV/EBITDA ~6.7 and a 3.6% yield. Technicals are oversold and an insider purchase shows conviction. Trade plan below for a mid-term rebound.
Fortrea is showing the kind of operating leverage investors want to see in a contract research organization: positive free cash flow ($196M last reported), improving book-to-bill (1.15x), and margin tailwinds driven by technology products like Fortrea Intelligent Technology. The stock is trading near $18.90 with technicals supportive and a favorabl…
Perpetua Resources is a development-stage play on the Stibnite Gold Project in Idaho that benefits from a $2.9 billion U.S. government loan commitment, attractive implied upside to historical highs, and improving technicals. The company remains pre-production with negative earnings and cash burn, so this is a conviction long trade sized for risk-to…
TransDigm’s pullback to $1,185 offers a chance to own a high-margin aerospace aftermarket platform that has consistent FCF and a clear acquisition runway. Valuation is elevated versus broad market multiples, but the company’s $2.74B quarterly revenue, $1.5B adjusted EBITDA and $2.436B free cash flow provide justification for a disciplined long-term…
Microsoft is the best-in-class AI infrastructure and software play that markets finally understand. Fundamentals - including $66.99B of free cash flow, 30% return on equity, and a conservative debt load - support continued multiple expansion as Azure AI wins enterprise wallets. Valuation is rich but reasonable given cash flow strength; this trade t…
Meta's stock is trading like its AI investments are a long-term drag. The numbers tell a different story: strong free cash flow, attractive ROE, and manageable leverage suggest the market is underpricing near-term monetization and optionality from AI and infrastructure deals. This trade targets a mid-term re-rate toward $700 with a $540 stop.
Phibro (PAHC) looks set to turn a recent acquisition into durable margin and cash-flow upside. The Zoetis medicated feed-additive portfolio and management continuity following a CEO transition create a clear operational catalyst. At a $1.53B market cap and EV/EBITDA of 8.95, the stock is reasonably valued for a company with improving revenue growth…
JOYY trades at a cheap valuation (P/B ~0.57, P/E ~17.8) despite improving technicals, an expanding BIGO footprint and a 6.4% yield. We outline a long trade with a $74.60 entry, $66 stop and $95 target over a long-term (180 trading days) horizon, plus mid-term profit-taking levels. Key risks include ad-market cyclicality, regulatory exposure in Asia…
Volkswagen's heavy exposure to China has historically insulated the group through cycles. That protective effect looks compromised: slowing end demand, intensifying local EV competition, and margin compression create a clear, actionable short trade for traders comfortable with higher risk. Plan: enter at $16.25, target $12.50, stop $19.00 - horizon…
Astera Labs ($290.30) has moved from high-growth breakout to a cash-generative, profitable infrastructure vendor with a new leg of growth coming from broader rack-scale AI deployments. Market cap is ~$50.2B, P/E ~136, and the share pullback looks like a low-volatility entry to ride continued data center spending. Trade plan: enter at $290.30, stop …
Dorchester Minerals (DMLP) reported a strong Q2 with operating revenues roughly doubling year-over-year and declared a robust distribution. The partnership is trading at a reasonable multiple for a cash-yielding royalty vehicle, and a recent acreage acquisition in the Williston Basin supports near-term production optionality. This is a mid-term (45…
Nvidia’s dominance in AI compute is priced for growth, but recent market weakness creates a repeatable entry opportunity. The company’s data-center engine generated $89.0B last quarter (92.5% of revenue) and sits on $127B of free cash flow. We recommend a mid-term buy on weakness with an entry at $215.00, stop at $200.00, and target of $260.00 over…
Citizens Financial Services (CZFS) has rallied toward its 52-week high after a string of better-than-expected quarters, but the stock still trades at a single-digit P/E and just over book value. For patient traders willing to buy a small pullback, the risk/reward is favorable with clear support levels and multiple near-term catalysts.
Vår Energi's clustered North Sea footprint and growing hub density are converting incremental production into outsized free cash flow. We see an asymmetric reward-risk over the next 180 trading days as the market re-prices the company closer to a cash-flow multiple rather than a pure growth multiple. Entry at $14.50, target $19.00, stop $12.00.
MarketWise is a small-cap subscription software platform that just reported accelerating billings and affirmed a $1.80 annual dividend. The business is generating strong cash flow, valuation is cheap on cash-flow metrics, and the stock yields materially. We outline a buy plan with a tight stop to limit downside and a target near the 52-week high fo…
Revolution Medicines just cleared a major regulatory hurdle with FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma. The approval unlocks what analysts peg as up to $11.5 billion in peak sales and converts the company from a pure clinical-stage name into a commercial oncology contender. Given the stock's recent pullbac…
MaxLinear (MXL) is benefiting from a surge in AI data-center connectivity demand and delivered strong near-term results and guidance. The stock is richly valued on classic multiples, but the business is posting double-digit and even triple-digit growth in its infrastructure products. This idea sizes a long trade aimed at capturing the next 180 trad…
PayPal rallied on solid TPV and a one-off free cash flow beat, but underlying branded checkout weakness, margin pressure, and a failed $60.50 takeover attempt leave the stock vulnerable. Technicals show bearish momentum and elevated short activity. We recommend a tactical short trade sized for a swing window as management execution must prove susta…
